Minister, last week, the publication of the Cass review's final report caused a significant degree of concern. What action is your Department going to take in light of that report's publication, and can you explain how puberty blockers, which were introduced in the UK merely for research trials, could come to be prescribed for routine clinical use despite not being licensed for such use or there being any meaningful evidence about their safety? How many children in Northern Ireland might those have been prescribed to?